- Home
- ANVS vs CMRX Comparison
ANVS vs CMRX Comparison
Compare ANVS & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- CMRX
- Stock Information
- Founded
- ANVS 2008
- CMRX 2000
- Country
- ANVS United States
- CMRX United States
- Employees
- ANVS N/A
- CMRX N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- CMRX Health Care
- Exchange
- ANVS Nasdaq
- CMRX Nasdaq
- Market Cap
- ANVS 110.4M
- CMRX 77.0M
- IPO Year
- ANVS 2020
- CMRX 2013
- Fundamental
- Price
- ANVS $9.57
- CMRX $0.93
- Analyst Decision
- ANVS Strong Buy
- CMRX Strong Buy
- Analyst Count
- ANVS 6
- CMRX 1
- Target Price
- ANVS $29.67
- CMRX $11.00
- AVG Volume (30 Days)
- ANVS 341.4K
- CMRX 119.4K
- Earning Date
- ANVS 11-06-2024
- CMRX 11-08-2024
- Dividend Yield
- ANVS N/A
- CMRX N/A
- EPS Growth
- ANVS N/A
- CMRX N/A
- EPS
- ANVS N/A
- CMRX N/A
- Revenue
- ANVS N/A
- CMRX $144,000.00
- Revenue This Year
- ANVS N/A
- CMRX $3,040.12
- Revenue Next Year
- ANVS N/A
- CMRX N/A
- P/E Ratio
- ANVS N/A
- CMRX N/A
- Revenue Growth
- ANVS N/A
- CMRX N/A
- 52 Week Low
- ANVS $4.53
- CMRX $0.75
- 52 Week High
- ANVS $22.49
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- ANVS 58.70
- CMRX 60.78
- Support Level
- ANVS $9.00
- CMRX $0.80
- Resistance Level
- ANVS $10.54
- CMRX $0.98
- Average True Range (ATR)
- ANVS 0.81
- CMRX 0.05
- MACD
- ANVS 0.12
- CMRX 0.01
- Stochastic Oscillator
- ANVS 74.57
- CMRX 83.33
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.